Antidote is a technology company.
Antidote has raised $3.0M across 1 funding round.
Antidote has raised $3.0M in total across 1 funding round.
Antidote is a digital health technology company focused on accelerating medical research by improving patient recruitment and engagement for clinical trials. It builds a precision recruitment platform that matches patients with suitable clinical trials using structured, machine-readable clinical trial data combined with a user-friendly interface. Antidote serves patients, researchers, and pharmaceutical companies by addressing the critical problem of low patient awareness and participation in clinical trials, which delays medical innovation. The company has demonstrated strong growth, having raised over $52 million in funding and generating approximately $11.6 million in revenue, with a workforce of about 50-55 employees spread across the US and UK[1][2][3].
Founded in 2010 originally as TrialReach, Antidote was launched to tackle the widespread issue that 85% of patients are unaware of clinical trials, and many find it difficult to locate trials they qualify for. This lack of patient participation causes 80% of trials to be delayed or closed, slowing medical progress. The founders, coming from backgrounds in pharmaceuticals, technology, and public health, envisioned a platform that would bridge the gap between medical research and patients by making clinical trial information accessible and actionable. The company rebranded to Antidote in 2016 and has since evolved to integrate data-driven technologies with personalized patient and site services, gaining early traction through its innovative approach to patient engagement and trial matching[1][2][3][4].
Antidote rides the growing trend of digital transformation in healthcare, particularly in clinical research, where patient recruitment remains a bottleneck. The timing is critical as the pharmaceutical industry faces increasing pressure to accelerate drug development timelines and reduce costs. Market forces such as the rise of personalized medicine, regulatory emphasis on diverse trial populations, and patient empowerment through digital tools favor Antidote’s model. By improving trial accessibility and patient engagement, Antidote influences the broader ecosystem by helping to speed up medical innovation, reduce trial delays, and ultimately bring new treatments to market faster[1][2][4].
Looking ahead, Antidote is well-positioned to expand its impact by further refining its AI-driven matching algorithms, scaling its global reach, and deepening partnerships with pharmaceutical companies and healthcare providers. Trends such as increased adoption of decentralized clinical trials and growing patient demand for transparency and involvement will shape its journey. Antidote’s influence is likely to grow as it continues to address systemic inefficiencies in clinical research, potentially becoming a central platform in the clinical trial ecosystem and a key enabler of faster, more inclusive medical breakthroughs[1][2][4].
Antidote has raised $3.0M in total across 1 funding round.
Antidote's investors include FasterCapital, Initial Capital.
Antidote has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2025 | $3.0M Seed | FasterCapital, Initial Capital |